The poor outcomes, especially in triple-negative breast cancer (TNBC), are largely due to lack of known therapeutic targets (e.g., estrogen receptor [ER] or human epidermal growth factor receptor 2 [HER2]), highlighting the crucial need to better understand the biology of this complex cancer and to develop better therapeutic strategies to improve patient survival [2]. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.